The Problem – ICU Acquired Weakness

Up to 80% of patients admitted to Intensive Care Units (ICUs) develop some form of neuromuscular dysfunction, which often leads to a much more serious complication known as ICU Acquired Weakness (ICUAW). ICUAW is a global muscle weakness that can develop in as little as a few hours after admission to the ICU and results in prolonged hospital stays (both in the ICU and afterwards in the ward), increased healthcare costs and reductions in health-related quality of life and expectancy.

1.2 Million

of US ICU patients develop ICUAW each year

$16.2 Billion

Increased cost to US Healthcare System due to ICUAW in mechanically ventilated patients

The Solution- MyokinE System

Health Discovery Labs has spent the last four years developing a revolutionary Electrical Muscle Stimulation (EMS) system called MyokinE, which provides a non-volitional exercise strategy (i.e., a muscle stimulation therapy that can be administered to unconscious patients) primarily intended for use with critically-ill patients who are at risk of developing ICUAW.  On average, the MyokinE system will reduce the length of stay in the ICU by 1.6 days for mechanically ventilated patients. 

MyokinE Cost vs. Savings

(per ICU patient using mechanical ventilation)

2,860% Hospital ROI

Market Validation

Health Discovery Labs has made significant progress since its inception in 2015.  In 2017, HDL was accepted into the highly-competitive Austin Technology Incubator, or ATI, which is the startup incubator at the University of Texas at Austin.  ATI harnesses business, government and academic resources to provide strategic counsel, operational guidance, and infrastructure support to its member companies to help them transition into successful, high growth technology businesses.  HDL has received tremendous support and encouragement from leading physicians in top hospitals in the US and abroad. HDL is in the process of developing clinical trials with Dell Seton, St. David’s Healthcare, and other leading institutions.   


Oussama Hassan, MD

Co-Founder & Chief Medical Officer 

Nephrologist specializing in kidney diseases, dialysis, and organ transplantation 


Alaa Hassan, MSEE

Co-Founder & Chief Technology Officer 

Technical lead with over 10 years experience guiding innovative medical products and ideas from concept to commercialization for startups and large international leaders in the healthcare space




  1. 1
    What It Means to Be OK
  2. 2
    Changing Intensive Care to Improve Life Afterward
  3. 3
    ICU-Acquired Weakness and Recovery from Critical Illness- NEJM 2014 (PMID: 24758618)
  4. 4
    Intensive care unit-acquired weakness: unanswered questions and targets for future research (PMID: 31069055)